CIDARA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.63 USD | -2.85% |
|
-7.27% | -20.47% |
| Apr. 25 | Top Premarket Gainers | MT |
| Apr. 25 | North American Morning Briefing : More Tech -2- | DJ |
Financials (USD)
| Sales 2024 * | 24.07M | Sales 2025 * | 42.86M | Capitalization | 57.61M |
|---|---|---|---|---|---|
| Net income 2024 * | -61M | Net income 2025 * | -40M | EV / Sales 2024 * | 2.39 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.34 x |
| P/E ratio 2024 * |
-0.98
x | P/E ratio 2025 * |
-2.31
x | Employees | 69 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cidara Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | -2.85% | ||
| 1 week | -7.27% | ||
| Current month | -31.36% | ||
| 1 month | -25.01% | ||
| 3 months | -5.02% | ||
| 6 months | -18.62% | ||
| Current year | -20.47% |
1 week
10.00
14.96
1 month
10.0024.40
Current year
10.0024.40
1 year
10.0029.60
3 years
8.0047.80
5 years
8.0089.00
10 years
8.00382.60
| Managers | Title | Age | Since |
|---|---|---|---|
Jeffrey Stein
CEO | Chief Executive Officer | 69 | 13-12-31 |
Preetam Shah
DFI | Director of Finance/CFO | 51 | 21-08-31 |
Les Tari
CTO | Chief Tech/Sci/R&D Officer | 57 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Burgess
CHM | Chairman | 62 | 14-03-31 |
| Director/Board Member | 69 | 14-03-31 | |
Jeffrey Stein
CEO | Chief Executive Officer | 69 | 13-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 12.63 | -2.85% | 200,108 |
| 24-04-25 | 13 | +5.78% | 753,807 |
| 24-04-24 | 12.29 | +19.90% | 326,436 |
| 24-04-23 | 10.25 | -0.27% | 96,083 |
| 24-04-22 | 10.28 | -24.54% | 192,657 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Companyâs portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
12.63
USD
Average target price
25
USD
Spread / Average Target
+97.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.47% | 57.61M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CDTX Stock
